Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS) - Thaçi, Diamant; Pinter, Andreas; Sebastian, Michael; Termeer, Christian; Sticherling, Michael; Gerdes, Sascha; Schäkel, Knut; Wegner, Sven; Krampe, Stefanie; Bartz, Holger; Rausch, Christian; Taut, Friedemann; et al. (British journal of dermatology, 2024)
Veröffentlicht: 22. Dezember 2023